Theriva Biologics, Inc. Contract Liability (Deferred Revenue)
Theriva Biologics, Inc. (TOVX) had Contract Liability (Deferred Revenue) of $906.00 thousand as of 2023-12-31, per its 10-K filed 2024-03-25.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2024-03-25
- 2023-12-31: Contract with Customer, Liability, Current $906.00K.
- 2023-09-30: Contract with Customer, Liability, Current $525.00K.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2023-12-31 | $906.00K 10-K · filed 2024-03-25 |
| 2023-09-30 | $525.00K 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |